Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I
Dispatch: Borealis Summit Puts Compass Pathways’ Minimal Support Model Under Microscope • IV Ketamine Outperforms IN Esketamine in Retrospective Study • Reunion Neuroscience Advances RE104 While Academic Preclinical Study of Psilocybin Raises Postpartum Questions • Mindstate Design Labs Completes Phase I Study, Teases First Fixed-Dose Combination Program • New York Assembly Discusses Psilocybin • and more…